跳至主要内容
临床试验/NCT00097526
NCT00097526已完成不适用

Bone Mineral Density in Adolescent Subjects With Growth Hormone Deficiency Who Are Completing Treatment With Nutropin AQ, Nutropin, or Protropin in the National Cooperative Growth Study (NCGS)

Genentech, Inc.0 个研究点目标入组 125 人开始时间: 2000年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
125

研究概览

简要总结

This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural indications.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
— 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan
  • Previous enrollment in the NCGS core study, 85-036
  • Tanner Stage 4 or greater
  • Either spontaneous or induced puberty
  • Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height

排除标准

  • Current therapy with a non Genentech GH product
  • Pregnancy (to avoid exposure to low levels of radiation from DXA scanners)
  • Bilateral hip replacement
  • Weight >130 kg (286 lb.)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验